DNMT3A and myelodysplastic syndrome: Very recently, Traina et al. reported that DNMT3A and/or TET2 mutations were the independent predictors for a favorable response to DNMT inhibitors of 5-azacytidine and/or decitabine in myelodysplastic syndromes and related neoplasms [31].